JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01877 JUNSHI BIO

Not Yet Opened 11-26 16:08:11

12.400

+0.040

+0.32%

High12.560	Low12.200	Vol969.60K
Open12.200	D1 Closing12.360	Amplitude2.91%
Mkt Cap12.22B	Tradable Cap2.72B	Total Shares985.69M
T/O11.99M	T/O Rate0.44%	Tradable Shares219.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"JUNSHI BIO","latestPrice":12.4,"timestamp":1732608491029,"preClose":12.36,"halted":0,"volume":969600,"delay":0,"floatShares":219000000,"shares":985689871,"eps":-2.48802540235968,"marketStatus":"Not Yet Opened","change":0.04,"latestTime":"11-26 16:08:11","open":12.2,"high":12.56,"low":12.2,"amount":11989535,"amplitude":0.029126,"askPrice":12.4,"askSize":2400,"bidPrice":12.36,"bidSize":1600,"shortable":3,"etf":0,"ttmEps":-1.9617715673193665,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732671000000},"marketStatusCode":0,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":12.36,"openAndCloseTimeList":[[1732584600000,1732593600000],[1732597200000,1732608000000]],"volumeRatio":0.8651642883394516,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"Shanghai Junshi Biosciences Co.,Ltd.","latestPrice":29.14,"timestamp":1732604400000,"preClose":29.34,"halted":0,"volume":4118100,"delay":0,"premium":"-60.32"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2484415451","title":"Junshi Bio Gets License to Develop Anti-Tumor Medication, Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484415451","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484415451?lang=en_us&edition=fundamental","pubTime":"2024-11-20 14:57","pubTimestamp":1732085821,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  secured a license agreement to distribute and manufacture two dual-targeting fusion proteins in mainland China, Hong Kong, Macau, and Taiwan, according to a Tuesday filing with the Hong Kong exchange.The dual-targeting fusion protein products are indicated for treating malignant tumors, the filing said.Junshi Bio will pay $1.5 million to the unnamed licensor as upfront payment, and up to 740 million yuan in aggregate milestone payments based on sales and research and development of the products, the filing said.The company will also pay royalties equivalent to a single-digit percentage of annual net sales, the filing said.Should the licensor grant rights to a third party to develop and sell the products outside of China, Macau, Hong Kong, and Taiwan, the licensor will pay Junshi Bio up to 20% of the sublicense revenue or $200 million, whichever is lower, the filing said.Shares jumped 4% in Hong Kong during Wednesday's trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","01877","BK1583","BK0239","688180","BK1515"],"gpt_icon":0},{"id":"2484614428","title":"Shanghai Junshi Biosciences' Unit Gets Marketing Approval for Cancer Drug by UK Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2484614428","media":"MT Newswires Live","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484614428?lang=en_us&edition=fundamental","pubTime":"2024-11-18 15:49","pubTimestamp":1731916146,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences (SHA:688180, HKG:1877) unit TopAlliance Biosciences has received marketing authorization and approval by UK Medicines and Healthcare products Regulatory Agency for its drug","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688180","BK0239","01877","BK1161","BK1583","BK1515"],"gpt_icon":0},{"id":"2483082663","title":"BRIEF-Shanghai Junshi Biosciences Announces Approval By MHRA For Marketing Of Toripalimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2483082663","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483082663?lang=en_us&edition=fundamental","pubTime":"2024-11-15 23:22","pubTimestamp":1731684159,"startTime":"0","endTime":"0","summary":"Nov 15 (Reuters) - Shanghai Junshi Biosciences Co Ltd :   * APPROVAL BY MHRA FOR MARKETING OF TORIPALIMABFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01877","BK1161","BK1583"],"gpt_icon":0},{"id":"2483792683","title":"Shanghai Junshi Biosciences - Approval by Mhra for Marketing of Toripalimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2483792683","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483792683?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:02","pubTimestamp":1731679343,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nFWN3MM0IY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK0239","BK1161","688180","BK1583","01877"],"gpt_icon":0},{"id":"2475606483","title":"Shanghai Junshi Biosciences Gets Approval to Market Immunotherapy Drug in Hong Kong, China","url":"https://stock-news.laohu8.com/highlight/detail?id=2475606483","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475606483?lang=en_us&edition=fundamental","pubTime":"2024-10-16 13:05","pubTimestamp":1729055125,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences (SHA:688180, HKG:1877) secured marketing approval of immunotherapy drug toripalimab in Hong Kong and China.Toripalimab is used to treat nasopharyngeal carcinoma either as a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4526","BK4585","BK4588","BK0239","HKD","688180","01877","BK1161","BK4023","BK1515","BK1583"],"gpt_icon":0},{"id":"2475802636","title":"BRIEF-Shanghai Junshi Biosciences Announces Approval For Marketing Of Toripalimab In Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2475802636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475802636?lang=en_us&edition=fundamental","pubTime":"2024-10-15 22:56","pubTimestamp":1729004196,"startTime":"0","endTime":"0","summary":"Oct 15 (Reuters) - Shanghai Junshi Biosciences Co Ltd :   * APPROVAL FOR MARKETING OF TORIPALIMAB IN HONG KONG SAR, CHINA   * UNIT GRANTED CERTIFICATE OF DRUG/PRODUCT REGISTRATION ISSUED BY PHARMACY AND POISONS BOARD OF HONG KONGFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","BK1515","BK1161","BK1583"],"gpt_icon":0},{"id":"2475507903","title":"Shanghai Junshi Biosciences - Approval for Marketing of Toripalimab in Hong Kong SAR, China","url":"https://stock-news.laohu8.com/highlight/detail?id=2475507903","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475507903?lang=en_us&edition=fundamental","pubTime":"2024-10-15 21:12","pubTimestamp":1728997940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nFWN3LR18U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","01877","BK0239","688180","BK1583"],"gpt_icon":0},{"id":"2475507492","title":"Shanghai Junshi Biosciences - Unit Granted Certificate of Drug/Product Registration Issued by Pharmacy and Poisons Board of Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2475507492","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475507492?lang=en_us&edition=fundamental","pubTime":"2024-10-15 21:12","pubTimestamp":1728997940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nFWN3LR18U:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK0239","01877","BK1161","BK1515","688180"],"gpt_icon":0},{"id":"2475786985","title":"Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2475786985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475786985?lang=en_us&edition=fundamental","pubTime":"2024-10-15 18:31","pubTimestamp":1728988280,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nFWN3LR0AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK0239","BK1583","01877","688180","BK1161"],"gpt_icon":0},{"id":"2475328118","title":"Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475328118","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475328118?lang=en_us&edition=fundamental","pubTime":"2024-10-15 06:30","pubTimestamp":1728945028,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. ( HKG:1877 ) shareholders would be excited to see that the share price has had a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-co-ltds-hkg1877-price-is-right-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01877","BK1515","BK1161","BK1583"],"gpt_icon":0},{"id":"1155119378","title":"Stock Track | JUNSHI BIO Stock Drops Despite Cholesterol Drug Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1155119378","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155119378?lang=en_us&edition=fundamental","pubTime":"2024-10-14 14:54","pubTimestamp":1728888869,"startTime":"0","endTime":"0","summary":"Shares of JUNSHI BIO, a leading biopharmaceutical company in China, plummeted by 8.10% on October 14th, despite receiving regulatory approval for its new cholesterol drug ongericimab injection from the National Medical Products Administration .However, the positive news of the regulatory approval did not translate into stock gains for JUNSHI BIO. The company's shares fell nearly 5% in Hong Kong trading and 1% in Shanghai, closing at HKD 14.58 on the day.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | JUNSHI BIO Stock Drops Despite Cholesterol Drug Approval","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01877"],"gpt_icon":0},{"id":"2475338629","title":"Shanghai Junshi Biosciences' Cholesterol Drug Gets NDA from NMPA; Shares Down 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475338629","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475338629?lang=en_us&edition=fundamental","pubTime":"2024-10-14 14:51","pubTimestamp":1728888688,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration (NMPA) approved Shanghai Junshi Biosciences' (HKG:1877) new drug application (NDA) for its cholesterol ongericimab injection, according to a Sunday fil","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","01877","BK4585","688180","BK0239","BK1583","BK4023","BK1161","BK1515","HKD","BK4526"],"gpt_icon":0},{"id":"2471823499","title":"Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?","url":"https://stock-news.laohu8.com/highlight/detail?id=2471823499","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471823499?lang=en_us&edition=fundamental","pubTime":"2024-09-30 14:25","pubTimestamp":1727677550,"startTime":"0","endTime":"0","summary":"Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/is-shanghai-junshi-biosciences-hkg1877-using-debt-sensibly-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01877","BK1515","BK1161","BK1583","EBIT"],"gpt_icon":0},{"id":"2470740875","title":"Junshi Biosciences Gets Rights for IAMA-001 Nasal Spray in Greater China; Shares Soar 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2470740875","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470740875?lang=en_us&edition=fundamental","pubTime":"2024-09-27 13:06","pubTimestamp":1727413594,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences'  unit, Shanghai JunTop Biosciences, received the exclusive license of IAMA-001 nasal spray, according to a Thursday disclosure on the Hong Kong Stock Exchange.Nanjing JSIAMA Biopharmaceuticals granted the pharmaceutical company the right to conduct research, develop, manufacture, and sell the product in the Greater China region. Both parties will share the interests of the product.JunTop will pay JSIAMA upfront payments worth 40 million yuan, research and development fees within China of 240 million yuan, and another $150 million for research and development milestones outside China.JSIAMA will also receive a single-digit percentage sales-based royalties on the annual net sales of the nasal spray, the Chinese pharmaceutical company said.The company's shares soared more than 10% on the Hong Kong bourse and jumped less than 6% on the Shanghai bourse.Price : $13.46, Change: $+1.2, Percent Change: +10.15%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4023","BK4526","688180","BK1583","BK4588","01877","BK1515","HKD","BK0239","BK4585","BK1161"],"gpt_icon":0},{"id":"2470478177","title":"Junshi Biosciences Gets Nod to Trial WJ47156 Tablets as Tumor Drug; Shares Soar 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2470478177","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470478177?lang=en_us&edition=fundamental","pubTime":"2024-09-27 12:47","pubTimestamp":1727412477,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  will conduct clinical trials on the drug, WJ47156 tablets, after securing the approval of the Chinese drug regulator, the National Medical Products Administration, according to a Thursday disclosure on the Hong Kong Stock Exchange.The pharmaceutical company will test the drug as a monotherapy for the treatment of advanced malignant tumors, the disclosure said.The company's shares soared more than 10% on the Hong Kong bourse and jumped less than 6% on the Shanghai bourse.Price : $13.46, Change: $+1.2, Percent Change: +10.15%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK4588","HKD","BK1583","BK4526","01877","688180","BK0239","BK1161","BK4023","BK4585"],"gpt_icon":0},{"id":"2470754262","title":"BRIEF-Shanghai Junshi Biosciences Says Js125 Received Notice Of Approval- For Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2470754262","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470754262?lang=en_us&edition=fundamental","pubTime":"2024-09-27 00:27","pubTimestamp":1727368022,"startTime":"0","endTime":"0","summary":"Sept 26 (Reuters) - Shanghai Junshi Biosciences :   * JS125 RECEIVED NOTICE OF APPROVAL- FOR CLINICAL TRIAL   * INVESTIGATIONAL NEW DRUG APPLICATION FOR WJ47156 TABLETS HAS BEEN APPROVED BY NMPAFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","BK1161","BK1515","BK1583"],"gpt_icon":0},{"id":"1107153024","title":"Stock Track | Junshi Biosciences Soars on New Licensing Deal for Nasal Spray Project","url":"https://stock-news.laohu8.com/highlight/detail?id=1107153024","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107153024?lang=en_us&edition=fundamental","pubTime":"2024-09-26 22:56","pubTimestamp":1727362598,"startTime":"0","endTime":"0","summary":"Shares of Junshi Biosciences  surged 6.61% on Wednesday, September 26th, to close at a higher level amid positive news regarding a new licensing agreement for one of its pharmaceutical projects.According to reports, a subsidiary of Junshi Biosciences, Shanghai Junshi Biosciences Co Ltd, entered into a license and cooperation agreement with Nanjing Jsiama Biopharmaceuticals for the development of a nasal spray product, dubbed IAMA-001.While details of the agreement remain undisclosed, investors s","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01877"],"gpt_icon":0},{"id":"2470753856","title":"BRIEF-Shanghai Junshi Biosciences Unit Entered Into License, Cooperation Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2470753856","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470753856?lang=en_us&edition=fundamental","pubTime":"2024-09-26 22:53","pubTimestamp":1727362426,"startTime":"0","endTime":"0","summary":"Sept 26 (Reuters) - Shanghai Junshi Biosciences Co Ltd :   * UNIT AND NANJING JSIAMA BIOPHARMACEUTICALS ENTERED INTO LICENSE, COOPERATION AGREEMENT FOR IAMA-001 NASAL SPRAY PROJECTFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01877","BK1161","BK1515"],"gpt_icon":0},{"id":"2470396287","title":"Shanghai Junshi Biosciences -  Unit and Nanjing Jsiama Biopharmaceuticals Entered Into License, Cooperation Agreement for Iama-001 Nasal Spray Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2470396287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470396287?lang=en_us&edition=fundamental","pubTime":"2024-09-26 21:20","pubTimestamp":1727356853,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240926:nFWN3L80VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","688180","BK1161","01877","BK1515","BK0239"],"gpt_icon":0},{"id":"2470736574","title":"Shanghai Junshi Biosciences -Js125 Received Notice of Approval- for Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2470736574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470736574?lang=en_us&edition=fundamental","pubTime":"2024-09-26 21:05","pubTimestamp":1727355930,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240926:nFWN3L80VO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01877","688180","BK1583","BK1515","BK0239"],"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.1401},{"period":"3month","weight":0.069},{"period":"6month","weight":0.0801},{"period":"1year","weight":-0.4273},{"period":"ytd","weight":-0.3621}],"compareEarnings":[{"period":"1week","weight":-0.0257},{"period":"1month","weight":-0.0695},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.051},{"period":"1year","weight":0.0932},{"period":"ytd","weight":0.1239}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases . The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.122873},{"month":2,"riseRate":0.833333,"avgChangeRate":0.02917},{"month":3,"riseRate":0.666667,"avgChangeRate":0.049114},{"month":4,"riseRate":0.833333,"avgChangeRate":0.112597},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.034116},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.02585},{"month":7,"riseRate":0.5,"avgChangeRate":-0.055172},{"month":8,"riseRate":0,"avgChangeRate":-0.083168},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.027724},{"month":10,"riseRate":0.333333,"avgChangeRate":0.015959},{"month":11,"riseRate":0.5,"avgChangeRate":0.048465},{"month":12,"riseRate":0.8,"avgChangeRate":0.175695}],"exchange":"SEHK","name":"JUNSHI BIO","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest JUNSHI BIO(01877) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"JUNSHI BIO,01877,JUNSHI BIO股票,JUNSHI BIO股票老虎,JUNSHI BIO股票老虎国际,JUNSHI BIO行情,JUNSHI BIO股票行情,JUNSHI BIO股价,JUNSHI BIO股市,JUNSHI BIO股票价格,JUNSHI BIO股票交易,JUNSHI BIO股票购买,JUNSHI BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"JUNSHI BIO(01877),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest JUNSHI BIO(01877) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}